Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

TitleWorkshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.
Publication TypeJournal Article
Year of Publication2017
AuthorsZloza A, A Palucka K, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong K-K, Bosenberg MW
JournalJ Immunother Cancer
Volume5
Issue1
Pagination77
Date Published2017 09 19
ISSN2051-1426
KeywordsAnimals, Disease Models, Animal, Humans, Immunotherapy, Mice, Molecular Targeted Therapy, Neoplasms, Societies, Scientific, Tumor Microenvironment
Abstract

Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, "Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy" as part of the SITC 31st Annual Meeting and Associated Programs on November 10, 2016 in National Harbor, MD. The workshop focused on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in cancer modeling that are anticipated in the near future. This full-day program provided an introduction to the most common immunocompetent and humanized models used in cancer immunology and immunotherapy research, and addressed the use of models to evaluate immune-targeting therapies. Here, we summarize the workshop presentations and subsequent panel discussion.

DOI10.1186/s40425-017-0278-6
Alternate JournalJ Immunother Cancer
PubMed ID28923102
PubMed Central IDPMC5604351
Grant ListP30 CA034196 / CA / NCI NIH HHS / United States
UL1 TR001863 / TR / NCATS NIH HHS / United States

Person Type: